A Phase II Randomized, Placebo-controlled, Double-blind, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamic Dose Response Relationship of IFX-1 in Patients Undergoing Complex Cardiac Surgery
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs IFX 1 (Primary)
- Indications Inflammation
- Focus Therapeutic Use
- Acronyms CARDIAC
- Sponsors InflaRx
- 14 Feb 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2016 New trial record